Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Undergraduate School

Harvard College

2011, Cambridge, MA

Graduate School

University of Oxford

2014, Oxford, United Kington

Medical School

Harvard Medical School

2018, Boston, MA

Internship

Internal Medicine

University of California, San Diego

2019, San Diego, CA

Residency

Radiation Oncology

Harvard Radiation Oncology Program

2023, Boston, MA

Certifications

  • American Board of Radiology (Radiation Oncology)

Professional History

Dr. Liu is an Assistant Professor of Radiation Oncology at Harvard Medical School and the Director of Sarcoma Radiation Oncology at Massachusetts General Hospital. He has a clinical focus on sarcomas and pediatric malignancies. He received his undergraduate degree summa cum laude from Harvard College, his doctorate from the University of Oxford as a Fulbright and Clarendon Scholar, and his medical degree from Harvard Medical School. Dr. Liu completed his residency in radiation oncology at the Harvard Radiation Oncology Program where he served as Chief Resident.

His research focuses on novel treatment strategies for sarcomas, diffuse midline gliomas, high-grade gliomas, and neuroblastomas; improving outcomes after radiation for patients with sarcomas and pediatric patients with cancer; developing treatment paradigms for rare diseases; and closing gaps in healthcare disparities for underrepresented patient populations. His research has been published in The Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, International Journal of Radiation Oncology • Biology • Physics, and Cancer, and Radiotherapy & Oncology. He also serves as an associate editor for Frontiers in Oncology. Dr. Liu teaches and mentors medical students and residents.

Publications

  1. Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma. Gynecol Oncol. 2025 Apr; 195:75-81. View Abstract

  2. Treatment Approach for Metastatic Intracranial Germinoma: A Multi-Institutional Experience. Pediatr Blood Cancer. 2025 May; 72(5):e31628. View Abstract

  3. The association between postoperative photon radiotherapy dose and disease control and salvage treatment in pediatric and adolescent ependymoma: a multi-institutional investigation. J Neurooncol. 2025 May; 173(1):167-177. View Abstract

  4. Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma. Curr Oncol. 2025 Feb 22; 32(3). View Abstract

  5. Multimodal deep learning improves recurrence risk prediction in pediatric low-grade gliomas. Neuro Oncol. 2025 Jan 12; 27(1):277-290. View Abstract

  6. A foundation model for generalized brain MRI analysis. medRxiv. 2024 Dec 03. View Abstract

  7. Changes in Merkel cell oncoprotein antibodies after radiation therapy in curatively treated Merkel cell carcinoma and association with recurrence. Cancer. 2024 Dec 15; 130(24):4267-4275. View Abstract

  8. Stepwise Transfer Learning for Expert-level Pediatric Brain Tumor MRI Segmentation in a Limited Data Scenario. Radiol Artif Intell. 2024 Jul; 6(4):e230254. View Abstract

  9. Longitudinal risk prediction for pediatric glioma with temporal deep learning. medRxiv. 2024 Jun 28. View Abstract

  10. Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field. Radiother Oncol. 2024 09; 198:110384. View Abstract

  11. Case Report: Low-grade glioma with NF1 loss of function mimicking diffuse intrinsic pontine glioma. Front Surg. 2024; 11:1356660. View Abstract

  12. Noninvasive Molecular Subtyping of Pediatric Low-Grade Glioma with Self-Supervised Transfer Learning. Radiol Artif Intell. 2024 May; 6(3):e230333. View Abstract

  13. Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning. medRxiv. 2023 Nov 22. View Abstract

  14. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. J Clin Oncol. 2024 Feb 01; 42(4):441-451. View Abstract

  15. Automated temporalis muscle quantification and growth charts for children through adulthood. Nat Commun. 2023 11 09; 14(1):6863. View Abstract

  16. Genetic architecture of the acute and persistent immune cell response after radiation exposure. Cell Genom. 2023 Nov 08; 3(11):100422. View Abstract

  17. Expert-level pediatric brain tumor segmentation in a limited data scenario with stepwise transfer learning. medRxiv. 2023 Sep 18. View Abstract

  18. Radiotherapy for Primary Pediatric Central Nervous System Malignancies: Current Treatment Paradigms and Future Directions. Pediatr Neurosurg. 2023; 58(5):356-366. View Abstract

  19. Clinical outcomes of radiation therapy for transgender and gender-expansive people with cancer. Front Oncol. 2023; 13:1135400. View Abstract

  20. Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors. Pediatr Blood Cancer. 2023 11; 70(11):e30652. View Abstract

  21. Multi-institutional Characterization of Outcomes for Pediatric and Young Adult Patients With High-Risk Myxopapillary Ependymoma After Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1174-1180. View Abstract

  22. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma. Front Immunol. 2023; 14:1148317. View Abstract

  23. Gender-Affirming Surgery and Cancer: Considerations for Radiation Oncologists for Pelvic Radiation in Transfeminine Patients. Int J Radiat Oncol Biol Phys. 2023 10 01; 117(2):301-311. View Abstract

  24. Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era. Neoplasia. 2023 Feb; 36:100857. View Abstract

  25. Low-dose proton radiotherapy for pediatric choroidal hemangioma: A case series. Pediatr Blood Cancer. 2022 12; 69(12):e29925. View Abstract

  26. A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma. Cancer Cell. 2022 09 12; 40(9):957-972.e10. View Abstract

  27. Clinical outcomes and considerations of gender-affirming care for transgender and gender-diverse pediatric and young adult patients with cancer. Pediatr Blood Cancer. 2023 01; 70(1):e29851. View Abstract

  28. Multi-institutional analysis of central nervous system germ cell tumors in patients with Down syndrome. Pediatr Blood Cancer. 2022 10; 69(10):e29830. View Abstract

  29. Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. Transplant Cell Ther. 2022 08; 28(8):502.e1-502.e12. View Abstract

  30. Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma. Radiother Oncol. 2022 08; 173:32-40. View Abstract

  31. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. J Neurooncol. 2022 May; 157(3):499-510. View Abstract

  32. "Per protocol" practice patterns for Children's Oncology Group trials within the radiation oncology community. Pediatr Blood Cancer. 2023 Aug; 70(8):e29673. View Abstract

  33. Surgical complications and clinical outcomes after dose-escalated trimodality therapy for non-small cell lung cancer in the era of intensity-modulated radiotherapy. Radiother Oncol. 2021 12; 165:44-51. View Abstract

  34. Prospective Longitudinal Assessment of Health-related Quality of Life in Patients With Brain Metastases Undergoing Radiation Therapy. Am J Clin Oncol. 2021 10 01; 44(10):536-543. View Abstract

  35. Clinical outcomes for pediatric patients receiving radiotherapy for solid tumor central nervous system metastases. Pediatr Blood Cancer. 2021 12; 68(12):e29331. View Abstract

  36. Harnessing Lactate Metabolism for Radiosensitization. Front Oncol. 2021; 11:672339. View Abstract

  37. Longitudinal multicentre retrospective cohort study of treatment outcomes in extramammary Paget disease. Br J Dermatol. 2021 07; 185(1):219-221. View Abstract

  38. Long-term outcomes of pediatric and young adult patients receiving radiotherapy for nonmalignant vascular anomalies. Pediatr Blood Cancer. 2021 06; 68(6):e28955. View Abstract

  39. Clinical outcomes of pediatric patients with autism spectrum disorder and other neurodevelopmental disorders and intracranial germ cell tumors. Pediatr Blood Cancer. 2021 08; 68(8):e28935. View Abstract

  40. Development and Implementation of an Online Adaptive Stereotactic Body Radiation Therapy Workflow for Treatment of Intracardiac Metastasis. Pract Radiat Oncol. 2021 Jul-Aug; 11(4):e395-e401. View Abstract

  41. Clinical Characteristics, Experiences, and Outcomes of Transgender Patients With Cancer. JAMA Oncol. 2021 Jan 01; 7(1):e205671. View Abstract

  42. A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):726-735. View Abstract

  43. Reirradiation practices for children with diffuse intrinsic pontine glioma. Neurooncol Pract. 2021 Feb; 8(1):68-74. View Abstract

  44. Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients. Adv Radiat Oncol. 2020 Nov-Dec; 5(6):1267-1273. View Abstract

  45. Improving Diversity and Inclusion in the Post-Coronavirus Disease 2019 Era Through a Radiation Oncology Intensive Shadowing Experience (RISE). Adv Radiat Oncol. 2021 Jan-Feb; 6(1):100566. View Abstract

  46. "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma. Front Immunol. 2020; 11:1947. View Abstract

  47. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View Abstract

  48. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 08 20; 38(24):2741-2752. View Abstract

  49. Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Ann Oncol. 2020 08; 31(8):1011-1020. View Abstract

  50. Macrophage Syk-PI3K? Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 03; 19(3):755-764. View Abstract

  51. Brainstem Injury in Pediatric Patients Receiving Posterior Fossa Photon Radiation. Int J Radiat Oncol Biol Phys. 2019 12 01; 105(5):1034-1042. View Abstract

  52. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer. Mol Cancer Ther. 2019 06; 18(6):1036-1044. View Abstract

  53. Towards a standard of care in oncology for transgender patients. Lancet Oncol. 2019 03; 20(3):331-333. View Abstract

  54. Risk stratification by somatic mutation burden in Ewing sarcoma. Cancer. 2019 04 15; 125(8):1357-1364. View Abstract

  55. Eliminating Daily Shifts, Tattoos, and Skin Marks: Streamlining Isocenter Localization With Treatment Plan Embedded Couch Values for External Beam Radiation Therapy. Pract Radiat Oncol. 2019 Jan; 9(1):e110-e117. View Abstract

  56. Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation. J Invest Dermatol. 2019 03; 139(3):591-599. View Abstract

  57. Characterization of long-term outcomes for pediatric patients with epithelioid hemangioma. Pediatr Blood Cancer. 2019 01; 66(1):e27451. View Abstract

  58. De novo ATP1A3 and compound heterozygous NLRP3 mutations in a child with autism spectrum disorder, episodic fatigue and somnolence, and muckle-wells syndrome. Mol Genet Metab Rep. 2018 Sep; 16:23-29. View Abstract

  59. Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Res. 2018 07 15; 78(14):4007-4021. View Abstract

  60. A cross-sectional survey of long-term outcomes for patients with diffuse capillary malformation with overgrowth. J Am Acad Dermatol. 2018 05; 78(5):1023-1025. View Abstract

  61. Contact Dermatitis Associated with Alopecia and Hyperpigmentation. Pediatr Dermatol. 2017 09; 34(5):624-625. View Abstract

  62. A Practical Approach to the Diagnosis and Management of Hair Loss in Children and Adolescents. Front Med (Lausanne). 2017; 4:112. View Abstract

  63. Colors. Acad Psychiatry. 2017 12; 41(6):759. View Abstract

  64. A Cautionary Tale: Risks of Radiation Therapy De-Escalation in Pediatric Malignancies. J Clin Oncol. 2017 08 01; 35(22):2471-2472. View Abstract

  65. Painful Ulcerative Lesions on Bilateral Lower Extremities. JAMA Dermatol. 2017 Feb 01; 153(2):223-224. View Abstract

  66. A novel de novo mutation in ATP1A3 and childhood-onset schizophrenia. Cold Spring Harb Mol Case Stud. 2016 Sep; 2(5):a001008. View Abstract

  67. Body habitus, serum albumin, and the outcomes after craniotomy for tumor: a National Surgical Quality Improvement Program analysis. J Neurosurg. 2017 Mar; 126(3):677-689. View Abstract

  68. Ctip1 Regulates the Balance between Specification of Distinct Projection Neuron Subtypes in Deep Cortical Layers. Cell Rep. 2016 05 03; 15(5):999-1012. View Abstract

  69. Thrombocytopenia and craniotomy for tumor: A National Surgical Quality Improvement Program analysis. Cancer. 2016 Jun 01; 122(11):1708-17. View Abstract

  70. The Evolutionarily Conserved Tre2/Bub2/Cdc16 (TBC), Lysin Motif (LysM), Domain Catalytic (TLDc) Domain Is Neuroprotective against Oxidative Stress. J Biol Chem. 2016 Feb 05; 291(6):2751-63. View Abstract

  71. Length of hospital stay after craniotomy for tumor: a National Surgical Quality Improvement Program analysis. Neurosurg Focus. 2015 Dec; 39(6):E12. View Abstract

  72. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1123-1129. View Abstract

  73. Oxr1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations. Hum Mol Genet. 2015 Jun 15; 24(12):3529-44. View Abstract

  74. Neuron-specific antioxidant OXR1 extends survival of a mouse model of amyotrophic lateral sclerosis. Brain. 2015 May; 138(Pt 5):1167-81. View Abstract
BESbswy